Literature DB >> 12213280

Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract.

M J Messenger1, L G Dawson, S Duty.   

Abstract

Metabotropic glutamate (mGlu) receptors in the basal ganglia motor loop may increase cell excitability (Group I) or modulate neurotransmitter release (Group I, II and III). Nigrostriatal tract degeneration in Parkinson's disease (PD) produces downstream pathological disturbances in glutamate and GABA transmission. The present study examined whether changes in mGlu receptor gene expression may either contribute to, or compensate for these pathological changes in transmission. In situ hybridisation studies examined the levels of mGlu receptor mRNA in motor loop regions in rats bearing a 6-hydroxydopamine-induced unilateral nigrostriatal tract lesion. Gene expression was reduced in the lesion compared to intact hemispheres for mGlu(1) in the substantia nigra pars compacta (SNc; 51.8+/-11.5%), mGlu(3) in the striatum and globus pallidus (11.7+/-2.8% and 18.9+/-1.4%, respectively) and mGlu(4) in the striatum and premotor cortex (13.8+/-2.7% and 15.8+/-5.5%, respectively). Loss of mGlu(1) mRNA in the SNc confirms that mGlu(1) is highly expressed on dopaminergic neurones where it may contribute to their vulnerability in PD. The down-regulation of mGlu(3) and mGlu(4) mRNA may reflect reduced transcriptional activity in response to increased levels of extracellular glutamate in these regions under parkinsonian conditions. These changes are likely to exacerbate the pathophysiological glutamate and GABA transmission within these regions in PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213280     DOI: 10.1016/s0028-3908(02)00090-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  24 in total

1.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates.

Authors:  R Sanchez-Pernaute; J-Q Wang; D Kuruppu; L Cao; W Tueckmantel; A Kozikowski; O Isacson; A-L Brownell
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

Review 3.  Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder.

Authors:  Sunil Goodwani; Hannah Saternos; Fawaz Alasmari; Youssef Sari
Journal:  Neurosci Biobehav Rev       Date:  2017-02-24       Impact factor: 8.989

4.  Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat.

Authors:  Nicholas MacInnes; Marcus J Messenger; Susan Duty
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

5.  Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment.

Authors:  Michael J Marino; David L Williams; Julie A O'Brien; Ornella Valenti; Terrence P McDonald; Michelle K Clements; Ruiping Wang; Anthony G DiLella; J Fred Hess; Gene G Kinney; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-30       Impact factor: 11.205

Review 6.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

7.  Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.

Authors:  Jonathan W Dickerson; P Jeffrey Conn
Journal:  Neurodegener Dis Manag       Date:  2012-04-01

Review 8.  Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.

Authors:  Susan Duty
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Subunit selective decrease of AMPA and metabotropic glutamate receptor mRNA expression in rat brain by systemic administration of the NMDA receptor blocker MK-801.

Authors:  Markus Storvik; Anni-Maija Lindén; Merja Lakso; Garry Wong
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

10.  Group I mGluRs evoke K-ATP current by intracellular Ca2+ mobilization in rat subthalamus neurons.

Authors:  Ke-Zhong Shen; Steven W Johnson
Journal:  J Pharmacol Exp Ther       Date:  2013-01-18       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.